Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

Article Authors: Andres Digenio, Richard L Dunbar, Veronica J Alexander, Marcus Hompesch, Linda Morrow, Richard G Lee, Mark J Graham, Steven G Hughes, Rosie Yu, Walter Singleton, Brenda F Baker, Sanjay Bhanot, Rosanne M Crooke


To determine the effects of volanesorsen (ISIS 304801), a second-generation 2′-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on triglyceride (TG) levels and insulin resistance in patients with type 2 diabetes.